Application of population screening principles to genetic screening for adult-onset conditions

Genetic Testing

Volumn 5, Issue 3, 2001, Pages 201-211

  Burke, Wylie ^a   Coughlin, Steven S ^b   Lee, Nancy C ^b   Weed, Douglas L ^c   Khoury, Muin J ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN;

CHRONIC DISEASE; CONFERENCE PAPER; DIAGNOSTIC VALUE; GENE MUTATION; GENETIC SCREENING; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MOLECULAR GENETICS; MORBIDITY; MORTALITY; PREDICTION; RISK BENEFIT ANALYSIS;

GENETICS AND REPRODUCTION;

ADULT; CHRONIC DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; POPULATION SURVEILLANCE; PUBLIC HEALTH PRACTICE;

EID: 0035693005     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/10906570152742245     Document Type: Article

References (99)

1. Hemochromatosis: Clinical implications of genetic testing
2. Long-term survival analysis in hereditary hemochromatosis
3. Statement on use of apolipoprotein E testing for Alzheimer disease
4. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. Adopted on February 20, 1996
5. Broadening the evidence base for evidence-based guidelines. A research agenda based on the work of the U.S. Preventive Services Task Force
6. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic
7. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer
8. Iron overload in African Americans
9. Long term results of venesection therapy in idiopathic haemochromatosis
10. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition
11. Guidelines for the molecular genetics predictive test in Huntington's disease: International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea
12. Ethical issues in genetic testing for Alzheimer's disease: Lessons from Huntington's disease
13. Recommendations for follow-up care of individuals with an inherited predisposition to cancer II. BRCA1 and BRCA2
14. Recommendations for follow-up care of individuals with an inherited predisposition to cancer I. Hereditary Nonpolyposis Colon Cancer
15. Hereditary hemochromatosis: Gene discovery and its implications for population-based screening
16. Contribution of different HFE genotypes to iron overload disease: A pooled analysis
17. Assessing the effectiveness of community screening programs
18. The periodic health examination
19. Psychological costs and benefits of predictive testing for Huntington's disease
20. Basic issues in population screening for cancer
21. BRCA1 - Lots of mutations, lots of dilemmas
22. The intersection of genetics, public health, and preventive medicine
23. Public health perspectives on testing for colorectal cancer susceptibility genes
24. BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives
25. Predictive testing for Huntington disease and the right not to know. Some ethical reflections
26. Screening for hemochromatosis: Phenotype versus genotype
27. Screening, ethics, and the law
28. Generic consent for genetic screening
29. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients
30. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium
31. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk
32. Criteria in screening test selection
33. Informed consent and BRCA1 testing
34. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent
35. Decoding" informed consent. Insights from women regarding breast cancer susceptibility testing
36. Detection of breast cancer by periodic X-ray examinations
37. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis
38. The human genome project. Prospects and implications for clinical medicine
39. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C)
40. Screening: Reasons to be cautious
41. Benefits and risks of emerging genetic technologies: The need for regulation
42. Are we ready to screen for inherited susceptibility to cancer?
43. Some public health issues in the current state of genetic testing for breast cancer in Australia
44. Predictive testing for Huntington disease: A psychologist's view
45. Genetic epidemiology and the future of disease prevention and public health
46. From genes to public health: The applications of genetic technology in disease prevention
47. Challenges in communicating genetics: A public health approach
48. An evaluation of some commonly used screening tests for heart disease and hypertension
49. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC
50. Screening and informed consent
51. Psychological issues in genetic testing for breast cancer susceptibility
52. BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes
53. Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals
54. Genetics of colonic cancer
55. Mass screening: Theory and ethics
56. Predisposition genetic testing for late-onset disorders in adults. A position paper of the National Society of Genetic Counselors
57. The need for anonymous genetic counseling and testing
58. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
59. Screening in Cancer. A report of a UICC International Workshop. Toronto, Canada, April 24-27, 1978
60. Principles of screening and of the evaluation of screening programs
61. Statement on use of DNA testing for presymptomatic identification of cancer risk
62. Long-term survival in patients with hereditary hemochromatosis
63. Quantitating familial cancer risk: A resource for clinical oncologists
64. Genetic epidemiology of coronary artery disease
65. Management of hereditary hemochromatosis
66. The clinical introduction of genetic testing for Alzheimer disease
67. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility
68. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation
69. Genetic discrimination and health insurance: A call for legislative action
70. Genetic testing: Employability, insurability, and health reform
71. Informed consent and Huntington disease: A model for communication
72. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden)
73. Preventive health services in adults
74. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
75. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
76. Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps
77. Population-based study of risk of breast cancer in carriers of BRCA2 mutation
78. The human genome project: Past, present, and future
79. The Tiresias complex: Huntington's disease as a paradigm of testing for late-onset disorders
80. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis
81. The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews
82. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13